David Feifel

Title(s)Senate Emeritus, Psychiatry
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Oxytocin as a therapeutic target for Schizophrenia
    NIH R01MH103421Apr 1, 2015 - Mar 31, 2021
    Role: Principal Investigator
    1/2-Anti-Psychotic Effects of Oxytocin
    NIH R34MH091285Jul 11, 2011 - Jun 30, 2014
    Role: Principal Investigator
    Neurotensin-1 Receptor as a Therapeutic Target for Schizophrenia
    NIH R01MH080910Mar 20, 2009 - Jan 31, 2015
    Role: Principal Investigator
    A Novel Animal Model of Relevance to Schizophrenia
    NIH R01MH070700Aug 5, 2005 - Jul 31, 2011
    Role: Principal Investigator
    Antipsychotic-Like Drug Effects of Neurotensin
    NIH R01MH062451Jun 1, 2002 - May 31, 2005
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Effects of chronic intranasal oxytocin on visual attention to faces vs. natural scenes in older adults. Psychoneuroendocrinology. 2024 Mar 04; 164:107018. Shoenfelt A, Pehlivanoglu D, Lin T, Ziaei M, Feifel D, Ebner NC. PMID: 38461634.
      View in: PubMed   Mentions:    Fields:    
    2. National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder. J Affect Disord. 2024 02 01; 346:221-222. Niciu MJ, Meisner RC, Carr BR, Farooqui AA, Feifel D, Kaplin A, Kendrick EJ, Kim PM, Schneck CD, Vande Voort JL, Parikh SV. PMID: 37940059.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Four-week intranasal oxytocin administration reduces attachment avoidance in older women. Horm Behav. 2023 Sep; 155:105413. Wright KA, Polk R, Lin T, Feifel D, Ebner NC. PMID: 37659357; PMCID: PMC10961710.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 2023 09; 48(10):1492-1499. Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E. PMID: 37443386; PMCID: PMC10425429.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    5. Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS. JCI Insight. 2023 02 22; 8(4). Zangen A, Zibman S, Tendler A, Barnea-Ygael N, Alyagon U, Blumberger DM, Grammer G, Shalev H, Gulevski T, Vapnik T, Bystritsky A, Filipcic I, Feifel D, Stein A, Deutsch F, Roth Y, George MS. PMID: 36692954; PMCID: PMC9977507.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023 04 14; 327:120-127. Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Pálenícek T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E. PMID: 36740140.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    7. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022 11 03; 387(18):1637-1648. Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Pálenícek T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. PMID: 36322843.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCTClinical Trials
    8. Age-Related Differences in Amygdala Activation Associated With Face Trustworthiness but No Evidence of Oxytocin Modulation. Front Psychol. 2022; 13:838642. Lin T, Pehlivanoglu D, Ziaei M, Liu P, Woods AJ, Feifel D, Fischer H, Ebner NC. PMID: 35814062; PMCID: PMC9262048.
      View in: PubMed   Mentions: 4  
    9. Intranasal oxytocin modulates the salience network in aging. Neuroimage. 2022 06; 253:119045. Liu P, Lin T, Feifel D, Ebner NC. PMID: 35259525; PMCID: PMC9450112.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Focus (Am Psychiatr Publ). 2022 Jan; 20(1):152-159. Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. PMID: 35746941; PMCID: PMC9063595.
      View in: PubMed   Mentions: 1  
    11. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021 Oct; 20(3):397-404. Zangen A, Moshe H, Martinez D, Barnea-Ygael N, Vapnik T, Bystritsky A, Duffy W, Toder D, Casuto L, Grosz ML, Nunes EV, Ward H, Tendler A, Feifel D, Morales O, Roth Y, Iosifescu DV, Winston J, Wirecki T, Stein A, Deutsch F, Li X, George MS. PMID: 34505368; PMCID: PMC8429333.
      View in: PubMed   Mentions: 44  
    12. Chronic oxytocin administration in older men modulates functional connectivity during animacy perception. Aging Brain. 2021; 1:100023. Valdes-Hernandez PA, Polk R, Horta M, Frazier I, Perez E, Ojeda M, Porges E, Cruz-Almeida Y, Feifel D, Ebner NC. PMID: 36911518; PMCID: PMC9997159.
      View in: PubMed   Mentions: 1  
    13. Reply to Tendler et al. Brain Stimul. 2021 Sep-Oct; 14(5):1216-1217. Taylor JJ, Newberger NG, Stern AP, Phillips A, Feifel D, Betensky RA, Press DZ. PMID: 34400377.
      View in: PubMed   Mentions:    Fields:    
    14. Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions. Brain Stimul. 2021 Jul-Aug; 14(4):965-973. Taylor JJ, Newberger NG, Stern AP, Phillips A, Feifel D, Betensky RA, Press DZ. PMID: 34133991.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial. Psychopharmacology (Berl). 2021 Sep; 238(9):2405-2418. Rung JM, Horta M, Tammi EM, Perez E, Ojeda MC, Lin T, Harris G, Somerville J, Salmeron D, Beltz SE, Sandesara B, Feifel D, Ebner NC. PMID: 33982141; PMCID: PMC8115997.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    16. Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial. Biol Psychiatry. 2021 11 15; 90(10):721-728. Isserles M, Tendler A, Roth Y, Bystritsky A, Blumberger DM, Ward H, Feifel D, Viner L, Duffy W, Zohar J, Keller CJ, Bhati MT, Etkin A, George MS, Filipcic I, Lapidus K, Casuto L, Vaishnavi S, Stein A, Deutsch L, Deutsch F, Morales O, Daskalakis ZJ, Zangen A, Ressler KJ. PMID: 34274108.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    17. A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin Case Rep. 2021 May; 9(5):e03869. Schwartz T, Trunko ME, Feifel D, Lopez E, Peterson D, Frank GKW, Kaye W. PMID: 34026123; PMCID: PMC8117825.
      View in: PubMed   Mentions: 13  
    18. Age and intranasal oxytocin effects on trust-related decisions after breach of trust: Behavioral and brain evidence. Psychol Aging. 2021 Feb; 36(1):10-21. Frazier I, Lin T, Liu P, Skarsten S, Feifel D, Ebner NC. PMID: 33705182; PMCID: PMC8202094.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Development of an innovative adult attention-deficit hyperactivity disorder clinic. Ment Health Clin. 2020 Sep; 10(5):296-300. Lee KC, Kim E, Kim J, Malcolm B, Kuo GM, Bird A, Feifel D. PMID: 33062556; PMCID: PMC7534811.
      View in: PubMed   Mentions: 3  
    20. Safety of Repeated Administration of Parenteral Ketamine for Depression. Pharmaceuticals (Basel). 2020 Jul 13; 13(7). Feifel D, Dadiomov D, C Lee K. PMID: 32668686; PMCID: PMC7408561.
      View in: PubMed   Mentions: 8  
    21. Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review. Neurosci Biobehav Rev. 2020 01; 108:1-23. Horta M, Kaylor K, Feifel D, Ebner NC. PMID: 31647964; PMCID: PMC6949379.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    22. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938. Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. PMID: 31109199.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    23. Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats. Neuropharmacology. 2019 05 15; 150:15-26. Roberts BZ, Young JW, He YV, Cope ZA, Shilling PD, Feifel D. PMID: 30844406; PMCID: PMC6500730.
      View in: PubMed   Mentions: 10     Fields:    Translation:Animals
    24. Oxytocin alters patterns of brain activity and amygdalar connectivity by age during dynamic facial emotion identification. Neurobiol Aging. 2019 06; 78:42-51. Horta M, Ziaei M, Lin T, Porges EC, Fischer H, Feifel D, Spreng RN, Ebner NC. PMID: 30870779; PMCID: PMC6545147.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    25. Roles and Qualifications of TMS Treatment Team Members. J Clin Psychiatry. 2018 Jan/Feb; 79(1). Feifel D, Dunner DL, Press DZ, Board of Directors and Clinical Standards Committee of the Clinical TMS Society. PMID: 29505183.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Network Meta-analysis in Mental Health Research. JAMA Psychiatry. 2017 08 01; 74(8):850-851. Feifel D. PMID: 28614557.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. J Affect Disord. 2017 10 15; 221:283-288. Feifel D, Malcolm B, Boggie D, Lee K. PMID: 28666206.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    28. Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects. Drug Dev Res. 2016 12; 77(8):489-494. Feifel D. PMID: 27888525.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil. J Vis Exp. 2016 10 04; (116). Feifel D, Pappas K. PMID: 27768049; PMCID: PMC5092131.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Oxytocin's effect on resting-state functional connectivity varies by age and sex. Psychoneuroendocrinology. 2016 07; 69:50-9. Ebner NC, Chen H, Porges E, Lin T, Fischer H, Feifel D, Cohen RA. PMID: 27032063; PMCID: PMC4942126.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    31. Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs. 2016 Mar; 30(3):193-208. Shilling PD, Feifel D. PMID: 26895254; PMCID: PMC5458113.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    32. Exposure to salient, dynamic sensory stimuli during development increases distractibility in adulthood. Sci Rep. 2016 Feb 17; 6:21129. Hadas I, Gal R, Bokovza L, Meiran N, Feifel D, Zangen A. PMID: 26882890; PMCID: PMC4756326.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    33. Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist. J Psychopharmacol. 2016 Mar; 30(3):312-7. Feifel D, Shilling PD, Fazlinejad AA, Melendez G. PMID: 26783230.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    34. Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit. Eur Neuropsychopharmacol. 2016 Mar; 26(3):626-30. Singh F, Nunag J, Muldoon G, Cadenhead KS, Pineda JA, Feifel D. PMID: 26727038.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. Oxytocin modulates meta-mood as a function of age and sex. Front Aging Neurosci. 2015; 7:175. Ebner NC, Horta M, Lin T, Feifel D, Fischer H, Cohen RA. PMID: 26441637; PMCID: PMC4565056.
      View in: PubMed   Mentions: 25  
    36. A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. Biol Psychiatry. 2016 Feb 01; 79(3):222-33. Feifel D, Shilling PD, MacDonald K. PMID: 26410353; PMCID: PMC5673255.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimals
    37. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimul. 2015 Jul-Aug; 8(4):787-94. Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS. PMID: 26143022.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    38. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depress Anxiety. 2015 Jun; 32(6):400-7. Acheson DT, Feifel D, Kamenski M, Mckinney R, Risbrough VB. PMID: 25826649.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    39. Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs. Behav Brain Res. 2015 Feb 01; 278:424-8. Feifel D, Shilling PD, Hillman J, Maisel M, Winfield J, Melendez G. PMID: 25447298; PMCID: PMC4382379.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    40. Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats. Exp Clin Psychopharmacol. 2014 Dec; 22(6):541-7. Keiser AA, Matazel KS, Esser MK, Feifel D, Prus AJ. PMID: 25222546; PMCID: PMC4250335.
      View in: PubMed   Mentions: 10     Fields:    Translation:Animals
    41. Oxytocin's role in anxiety: a critical appraisal. Brain Res. 2014 Sep 11; 1580:22-56. MacDonald K, Feifel D. PMID: 24468203.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    42. Developing Research Domain Criteria (RDoC) to improve diagnosis and treatment of social deficits in psychiatric disorders: the Mirror Neuron System as a model. Schizophr Res. 2013 Dec; 151(1-3):293-4. Singh F, Feifel D. PMID: 24094678.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    43. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting. J Emerg Med. 2013 Dec; 45(6):901-8. Wilson MP, MacDonald K, Vilke GM, Ronquillo L, Feifel D. PMID: 24071032.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Assessment of attention in male and female Brattleboro rats using a self-paced five-choice serial reaction time task. Brain Res. 2013 Nov 06; 1537:174-9. Berquist Ii MD, Mooney-Leber SM, Feifel D, Prus AJ. PMID: 24055104.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    45. Not disappointed by anxiety: a reply to Cardoso and Ellenbogen's commentary "Oxytocin and psychotherapy: keeping context and person in mind". Psychoneuroendocrinology. 2013 Dec; 38(12):3173-5. MacDonald K, Feifel D, Brüne M, Lamb K, Wilson MP, Golshan S, MacDonald T. PMID: 24035602.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Limited evidence that benzodiazepines are beneficial in the treatment of disturbed behaviour. Evid Based Ment Health. 2013 Nov; 16(4):111. Feifel D. PMID: 23956251.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology. 2013 Dec; 38(12):2831-43. MacDonald K, MacDonald TM, Brüne M, Lamb K, Wilson MP, Golshan S, Feifel D. PMID: 23810433.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    48. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology (Berl). 2013 Sep; 229(1):199-208. Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V. PMID: 23644911; PMCID: PMC5458114.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    49. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci. 2013; 7:35. Macdonald K, Feifel D. PMID: 23508240; PMCID: PMC3597931.
      View in: PubMed   Mentions: 67  
    50. In reply:. West J Emerg Med. 2012 Dec; 13(6):536-7. Feifel D, Wilson MP, Pepper D, Currier GW, Holloman G. PMID: 23875056; PMCID: PMC3715651.
      View in: PubMed   Mentions:    Fields:    
    51. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res. 2012 Aug; 139(1-3):207-10. Feifel D, Macdonald K, Cobb P, Minassian A. PMID: 22682705.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    52. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012 Jun; 32(3):317-22. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, Cobb P, Perez R, Galangue B, Feifel D. PMID: 22544013.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    53. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2014 Feb; 18(2):133-44. Arnold VK, Feifel D, Earl CQ, Yang R, Adler LA. PMID: 22617860.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    54. Dramatic improvement in sexual function induced by intranasal oxytocin. J Sex Med. 2012 May; 9(5):1407-10. MacDonald K, Feifel D. PMID: 22458365.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    55. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012 Feb; 13(1):26-34. Wilson MP, Pepper D, Currier GW, Holloman GH, Feifel D. PMID: 22461918; PMCID: PMC3298219.
      View in: PubMed   Mentions: 83     Fields:    
    56. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology. 2012 Jan; 37(1):304-5. Feifel D. PMID: 22157870; PMCID: PMC3238071.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012 Jun; 24(3):130-46. Macdonald K, Feifel D. PMID: 22736892; PMCID: PMC3378061.
      View in: PubMed   Mentions: 36     Fields:    
    58. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Oct; 72(10):1313-21. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spyker DA, Cassella JV. PMID: 21294997.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    59. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol. 2012 May; 22(5):374-8. Feifel D, Shilling PD, Belcher AM. PMID: 21962914; PMCID: PMC4208693.
      View in: PubMed   Mentions: 16     Fields:    Translation:Animals
    60. Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012 Feb; 219(3):715-25. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD. PMID: 21748252.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    61. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med. 2012 Nov; 43(5):790-7. Wilson MP, MacDonald K, Vilke GM, Feifel D. PMID: 21601409.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    62. Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci. 2011 Apr; 125(2):268-72. Feifel D, Shilling PD, Melendez G. PMID: 21463026; PMCID: PMC3079344.
      View in: PubMed   Mentions: 10     Fields:    Translation:Animals
    63. Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother. 2011 Feb; 11(2):157-9. Feifel D. PMID: 21306203.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    64. A Naturalistic, Single-blind Comparison of Rapid Dose Administration of Divalproex ER Versus Quetiapine in Patients with Acute Bipolar Mania. Innov Clin Neurosci. 2011 Jan; 8(1):29-35. Feifel D, Galangue B, Macdonald K, Cobb P, Dinca A, Becker O, Cooper J, Hadley A. PMID: 21311705; PMCID: PMC3036552.
      View in: PubMed   Mentions: 2  
    65. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011 Jan; 198(1):51-8. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella JV. PMID: 21200077.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    66. Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy. J Psychopharmacol. 2011 Jun; 25(6):836-41. Feifel D, Shilling PD, Melendez G. PMID: 21106605; PMCID: PMC4209717.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    67. Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep. 2010 Aug; 12(4):327-34. Feifel D, Shilling PD. PMID: 20544314; PMCID: PMC2895894.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    68. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010 Oct 01; 68(7):678-80. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. PMID: 20615494.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    69. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry. 2010 Jul-Aug; 32(4):443-5. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, Tallian K, Becker O, Feifel D. PMID: 20633750.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    70. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. J Emerg Med. 2012 Nov; 43(5):889-96. Wilson MP, MacDonald K, Vilke GM, Feifel D. PMID: 20542400.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    71. Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity. Behav Brain Res. 2010 Oct 15; 212(2):174-8. Feifel D, Pang Z, Pang Z, Shilling PD, Melendez G, Schreiber R, Button D. PMID: 20399236; PMCID: PMC2895158.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    72. The Use of Placebo-Controlled Clinical Trials for the Approval of Psychiatric Drugs: Part II-Ethical Considerations Related to the Individual Participant. Psychiatry (Edgmont). 2009 Dec; 6(12):19-25. Feifel D. PMID: 20104288; PMCID: PMC2811140.
      View in: PubMed   Mentions: 2  
    73. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology. 2010 Jan; 58(1):195-8. Feifel D, Goldenberg J, Melendez G, Shilling PD. PMID: 19596358; PMCID: PMC2784133.
      View in: PubMed   Mentions: 25     Fields:    Translation:Animals
    74. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology. 2010 Jan; 58(1):173-8. Feifel D, Pang Z, Shilling PD, Melendez G, Schreiber R, Button D. PMID: 19596359; PMCID: PMC2784210.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    75. The Psychiatric Emergency Research Collaboration-01: methods and results. Gen Hosp Psychiatry. 2009 Nov-Dec; 31(6):515-22. Boudreaux ED, Allen MH, Claassen C, Currier GW, Bertman L, Glick R, Park J, Feifel D, Camargo CA, PERC. PMID: 19892209; PMCID: PMC2852101.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    76. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009 Apr; 70(4):526-39. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. PMID: 19358790.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    77. The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology. 2009 Jul; 34(8):2011-8. Feifel D, Mexal S, Melendez G, Liu PY, Goldenberg JR, Shilling PD. PMID: 19322170; PMCID: PMC2744457.
      View in: PubMed   Mentions: 28     Fields:    Translation:Animals
    78. The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good". Psychiatry (Edgmont). 2009 Mar; 6(3):41-3. Feifel D. PMID: 19724754; PMCID: PMC2719456.
      View in: PubMed   Mentions: 4  
    79. The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol Biochem Behav. 2008 Oct; 90(4):748-52. Shilling PD, Feifel D. PMID: 18577396; PMCID: PMC4215568.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    80. Transforming the psychiatric inpatient unit from short-term pseudo-asylum care to state-of-the-art treatment setting. Psychiatry (Edgmont). 2008 Sep; 5(9):47-50. Feifel D. PMID: 19727261; PMCID: PMC2687088.
      View in: PubMed   Mentions: 2  
    81. Commentary: why diagnose and treat ADHD in adults? Postgrad Med. 2008 Sep; 120(3):13-5. Feifel D. PMID: 18824821.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    82. Attention-deficit/hyperactivity disorder in adults: recognition and diagnosis of this often-overlooked condition. Postgrad Med. 2008 Sep; 120(3):39-47. Feifel D, MacDonald K. PMID: 18824824.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    83. Prepulse inhibition of startle in adults with ADHD. J Psychiatr Res. 2009 Jan; 43(4):484-9. Feifel D, Minassian A, Perry W. PMID: 18674783; PMCID: PMC2669714.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    84. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology (Berl). 2008 Oct; 200(2):197-203. Feifel D, Melendez G, Murray RJ, Tina Tran DN, Rullan MA, Shilling PD. PMID: 18568338; PMCID: PMC2755044.
      View in: PubMed   Mentions: 19     Fields:    Translation:Animals
    85. Use of risperidone long-acting injectable in a rural border community clinic in southern california. Psychiatry (Edgmont). 2008 Jun; 5(6):43-9. Camacho A, Ng B, Galangue B, Feifel D. PMID: 19727284; PMCID: PMC2695749.
      View in: PubMed   Mentions: 3  
    86. More depressing news on antidepressants: should we panic? Psychiatry (Edgmont). 2008 Apr; 5(4):35-6. Feifel D. PMID: 19727307; PMCID: PMC2719549.
      View in: PubMed   Mentions: 2  
    87. Treatment of autistic children. Psychiatry (Edgmont). 2008 Feb; 5(2):35-7. Cascade EF, Kalali AH, Feifel D. PMID: 19727292; PMCID: PMC2708111.
      View in: PubMed   Mentions: 1  
    88. ADHD in adults: the invisible rhinoceros. Psychiatry (Edgmont). 2007 Dec; 4(12):60-2. Feifel D. PMID: 20436766; PMCID: PMC2861517.
      View in: PubMed   Mentions: 2  
    89. Daytrana: the first year. Psychiatry (Edgmont). 2007 Oct; 4(10):16-7. Cascade EF, Kalali AH, Feifel D. PMID: 20428306; PMCID: PMC2860521.
      View in: PubMed   Mentions: 1  
    90. An atomoxetine tutorial. Psychiatry (Edgmont). 2007 Aug; 4(8):35-8. Feifel D. PMID: 20532025; PMCID: PMC2880947.
      View in: PubMed   Mentions:
    91. Dosing of divalproex extended release. J Clin Psychiatry. 2007 Jul; 68(7):1146-7; author reply 1147. Feifel D. PMID: 17685756.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    92. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res. 2007 Aug 06; 181(2):278-86. Feifel D, Melendez G, Priebe K, Shilling PD. PMID: 17559953.
      View in: PubMed   Mentions: 21     Fields:    Translation:Animals
    93. Strattera: ups, downs, and emerging uses. Psychiatry (Edgmont). 2007 Apr; 4(4):23-5. Cascade EF, Kalali AH, Feifel D. PMID: 20711324; PMCID: PMC2921235.
      View in: PubMed   Mentions: 1  
    94. The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats. J Gen Psychol. 2007 Apr; 134(2):173-82. Feifel D, Priebe K. PMID: 17503693.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    95. Time to feel good: the therapeutic time course of antidepressants. Psychiatry (Edgmont). 2007 Mar; 4(3):25-7. Feifel D. PMID: 20805906; PMCID: PMC2922354.
      View in: PubMed   Mentions:
    96. When common clinical practice meets evidence-based medicine. Psychiatry (Edgmont). 2006 Dec; 3(12):36-8. Feifel D. PMID: 20877554; PMCID: PMC2945895.
      View in: PubMed   Mentions: 1  
    97. The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophr Res. 2007 Jan; 89(1-3):225-31. Minassian A, Feifel D, Perry W. PMID: 17005374; PMCID: PMC2676911.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    98. Recent changes in prescriptions for antipsychotics in children and adolescents. Psychiatry (Edgmont). 2006 Sep; 3(9):18-20. Cascade EF, Kalali AH, Penn JV, Feifel D. PMID: 20975824; PMCID: PMC2963464.
      View in: PubMed   Mentions: 2  
    99. Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry. 2006 Dec 01; 60(11):1278-81. Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D. PMID: 16814260.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    100. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006 Apr; 67(4):554-66. Ballon JS, Feifel D. PMID: 16669720.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansAnimals
    101. Rapid oral loading of extended release divalproex in patients with acute mania. Gen Hosp Psychiatry. 2005 May-Jun; 27(3):218-21. Miller BP, Perry W, Moutier CY, Robinson SK, Feifel D. PMID: 15882770.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    102. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004 Nov; 43(11):1406-14. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. PMID: 15502600.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    103. Inhibitory deficits in ocular motor behavior in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004 Sep 01; 56(5):333-9. Feifel D, Farber RH, Clementz BA, Perry W, Anllo-Vento L. PMID: 15336515.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    104. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist. Psychopharmacology (Berl). 2004 Sep; 175(3):353-9. Shilling PD, Melendez G, Priebe K, Richelson E, Feifel D. PMID: 15107967.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    105. Prepulse inhibition in patients with non-psychotic major depressive disorder. J Affect Disord. 2004 Aug; 81(2):179-84. Perry W, Minassian A, Feifel D. PMID: 15306146.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    106. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology. 2004 Apr; 29(4):731-8. Feifel D, Melendez G, Shilling PD. PMID: 14760394.
      View in: PubMed   Mentions: 27     Fields:    Translation:Animals
    107. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004 Mar; 65(3):386-94. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM. PMID: 15096079.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    108. Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. Neurosci Lett. 2003 Sep 18; 348(3):147-50. Feifel D, Shilling PD, Kuczenski R, Segal DS. PMID: 12932815.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    109. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav Brain Res. 2003 Jul 14; 143(1):7-14. Shilling PD, Richelson E, Feifel D. PMID: 12842291.
      View in: PubMed   Mentions: 19     Fields:    Translation:Animals
    110. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology. 2003 Apr; 28(4):651-3. Feifel D, Melendez G, Shilling PD. PMID: 12655309.
      View in: PubMed   Mentions: 20     Fields:    Translation:Animals
    111. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002 Aug; 159(8):1375-81. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. PMID: 12153831.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    112. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. Psychopharmacology (Berl). 2002 Jul; 162(2):138-46. Feifel D, Priebe K, Johnstone-Miller E, Morgan CJ. PMID: 12110991.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    113. Decreased haloperidol-induced potentiation of zif268 mRNA expression in the nucleus accumbens shell and the dorsal lateral striatum of rats lacking cholecystokinin-A receptors. Synapse. 2002 Feb; 43(2):134-8. Shilling PD, Feifel D. PMID: 11754493.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    114. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002 Feb; 63(2):169. Feifel D, Moutier CY, Perry W. PMID: 11874225.
      View in: PubMed   Mentions:    Fields:    
    115. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry. 2001 Sep 15; 50(6):425-33. Feifel D, Priebe K. PMID: 11566159.
      View in: PubMed   Mentions: 13     Fields:    Translation:Animals
    116. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry. 2001 Sep 15; 50(6):418-24. Perry W, Minassian A, Feifel D, Braff DL. PMID: 11566158.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    117. Startle and sensorimotor gating in rats lacking CCK-A receptors. Neuropsychopharmacology. 2001 Jun; 24(6):663-70. Feifel D, Priebe K, Shilling PD. PMID: 11331146.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    118. Amphetamine-induced zif268 mRNA expression in the medial posterior nucleus accumbens in cholecystokinin-A receptor mutant rats. Neurosci Lett. 2000 Mar 03; 281(1):17-20. Shilling PD, Feifel D, Kelsoe JR. PMID: 10686405.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    119. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry. 2000; 61 Suppl 14:27-32. Feifel D. PMID: 11154014.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    120. Effects of neurotensin administered into the ventral tegmental area on prepulse inhibition of startle. Behav Brain Res. 1999 Dec; 106(1-2):189-93. Feifel D, Reza TL. PMID: 10595435.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    121. Individual differences in prepulse inhibition of startle as a measure of individual dopamine function. Behav Neurosci. 1999 Oct; 113(5):1020-9. Feifel D. PMID: 10571484.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    122. Attitudes toward psychiatry as a prospective career among students entering medical school. Am J Psychiatry. 1999 Sep; 156(9):1397-402. Feifel D, Moutier CY, Swerdlow NR. PMID: 10484951.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    123. The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl). 1999 Sep; 146(2):175-9. Feifel D, Priebe K. PMID: 10525752.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    124. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther. 1999 Feb; 288(2):710-3. Feifel D, Reza TL, Wustrow DJ, Davis MD. PMID: 9918579.
      View in: PubMed   Mentions: 30     Fields:    Translation:Animals
    125. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis. Neuropsychopharmacology. 1999 Feb; 20(2):141-9. Feifel D, Reza T, Robeck S. PMID: 9885794.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    126. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl). 1999 Jan; 141(1):93-8. Feifel D, Reza T. PMID: 9952070.
      View in: PubMed   Mentions: 41     Fields:    Translation:Animals
    127. Cysteamine blocks amphetamine-induced deficits in sensorimotor gating. Pharmacol Biochem Behav. 1997 Nov; 58(3):689-93. Feifel D, Minor KL. PMID: 9329060.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    128. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997 Jun 20; 760(1-2):80-4. Feifel D, Minor KL, Dulawa S, Swerdlow NR. PMID: 9237521.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    129. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci Lett. 1997 Jun 20; 229(1):5-8. Feifel D, Swerdlow NR. PMID: 9224788.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    130. Iron overload among a psychiatric outpatient population. J Clin Psychiatry. 1997 Feb; 58(2):74-8. Feifel D, Young CW. PMID: 9062376.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    131. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides. 1997; 18(9):1457-60. Feifel D, Reza TL, Robeck SL. PMID: 9392852.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    132. Attention-deficit hyperactivity disorder in adults. Postgrad Med. 1996 Sep; 100(3):207-11, 215-8. Feifel D. PMID: 8795655.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    133. Intraventricular but not intraparaventricular nucleus metergoline elicits feeding in satiated rats. Am J Physiol. 1994 May; 266(5 Pt 2):R1562-7. Coscina DV, Feifel D, Nobrega JN, Currie PJ. PMID: 8203633.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    134. Growth hormone-regulatory peptides (GHRH and somatostatin) and feeding: a model for the integration of central and peripheral function. Neurosci Biobehav Rev. 1994; 18(3):421-33. Feifel D, Vaccarino FJ. PMID: 7984360.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    135. Evidence for a common neural mechanism mediating growth hormone-releasing factor-induced and somatostatin-induced feeding. Neuroendocrinology. 1993; 57(2):299-305. Feifel D, Vaccarino FJ, Rivier J, Vale WW. PMID: 8099720.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    136. Feeding effects of growth hormone-releasing factor in rats are photoperiod sensitive. Behav Neurosci. 1989 Aug; 103(4):824-30. Feifel D, Vaccarino FJ. PMID: 2504226.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    David's Networks
    Concepts (380)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (27)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California